๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› B Cell Malignancies
Clinical trial register · China

B Cell Malignancies Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shenzhen 3 Shanghai 2 Nanjing 2 Tianjin 1 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shenzhen3 Shanghai2 Nanjing2 Tianjin1 Hangzhou1
All 14 locations
Target enrolment
to

B Cell Malignancies trials in China

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CD19/70 Bi-specific CAR-T Cell Therapy
NCT05436496B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
CD19/22 Bi-specific CAR-T Cell Therapy
NCT05432882B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
60
Shenzhen
2027-06-01
Not yet open
4SCAR19U T Cells Targeting B Cell Malignancies
NCT05995015B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2026-12-31
Recruiting
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
NCT07349849B-cell Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1
47
Chongqing
2025-12-20
Recruiting
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
NCT07065279B-cell Malignancies
DrugJY231
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Not applicable
36
Kunming
2025-07
Recruiting
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
NCT06958679B-cell Malignancies, Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
132
Tianjin
2025-04-03
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
AstraZeneca
Phase 1/2
174
Hangzhou, Shanghai
2024-09-18
Recruiting
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
NCT06375161B Cell Malignancies
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase EARLY_PHASE1
12
Shanghai
2023-12-11
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
NCT05683717B-Cell Malignancies
TransThera Sciences (Nanjing), Inc.
Phase 1
37
Nanjing
2023-03-30
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/b-cell-malignancies

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition B Cell Malignancies.

How many B Cell Malignancies trials are recruiting in China?

6 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (B Cell Malignancies), 11 studies
PhaseStudiesRecruitingShare
Phase 14236.4%
Phase 1/23127.3%
Phase EARLY_PHASE12218.2%
Not applicable119.1%
Phase 3109.1%

Most active sponsors

Lead sponsors with the most studies (B Cell Malignancies)
Lead sponsorStudiesRecruiting
Shenzhen Geno-Immune Medical Institute30
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China11
AbbVie10
AstraZeneca11
BeOne Medicines10
CSPC Megalith Biopharmaceutical Co.,Ltd.11
Shanghai Tongji Hospital, Tongji University School of Medicine11
TransThera Sciences (Nanjing), Inc.11
Xinqiao Hospital of Chongqing11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.